Enabling the future of regenerative medicine

Cell Therapy
for All.

At TreeFrog, we are driven to make transformative regenerative medicine a reality, enabling the treatment of millions suffering around the world.

Scroll

The next frontier

Regenerative medicine. The next frontier.

Every day, millions of people live with diseases that cannot be cured by today’s medicines. The promise of regenerative medicine is simple but profound: to help the body heal by restoring the cells lost to disease.

The potential is huge, particularly for diseases of major organs such as the central nervous system, heart, liver and pancreas.

No cure exists for any of these diseases. But hope does. Advances in regenerative medicine offer the possibility of moving beyond symptom management toward meaningful recovery, bringing a brighter future to patients and families, and changing their lives forever.

At TreeFrog, we see a future where these life-changing therapies are accessible to every patient who could benefit from them.
Liver microtissue fluorescence microscopy

How do we plan to do this?

Our vision is to be the trusted engine for regenerative medicine — advancing restorative medicines through world class technology and deep therapeutic partnerships.

We have developed the only 3D biomimetic platform designed to overcome the challenges of regenerative medicine.

— Where to begin

Who we are.

To achieve our purpose of bringing these transformative therapies to patients, we bring the best science, technology, people and partnerships together.

— 01 / Platform

C-Stem.

The GMPc platform solving the manufacturing bottleneck of cell therapy at scale.

Dive into the platform →
— 02 / Pipeline

Our Pipeline.

A pipeline of owned and partnered assets in Parkinson’s Disease and Liver.

Explore the pipeline →
— 03 / Partnering

Your pipeline,
powered by C-Stem.

The C-Stem™ platform, in-licensed or co-developed — choose your route to clinical scale.

Partner with us →
— 04 / About

The team.

A talented ecosystem of the best executives from biophysics, biology, engineering and industry.

Meet the team →
— The challenge

Cell therapy is transformative.
But not (yet) scalable.

Regenerative cell therapies have the potential to cure chronic and degenerative diseases. Yet today, most remain at early clinical development stages due to scalability limitations.

— The Why

Manufacturing is complex and costly, production volumes are too low, and scaling compromises quality and consistency.

— The consequence

Breakthrough science
that cannot reach millions.

Our position
01
Manufacturing scale
Unlocks access.
02
Unique 3D microtissue
Better efficacy & safety.
03
Integrated encapsulation & differentiation
Faster, high-quality development.

We believe TreeFrog is the future of regenerative medicine. We are the only company to combine all three.

Why partner with us  →
– How we create value

Two pathways into C-Stemchoose the one that fits your strategy.

– Path A

C-Stem platform licensing.

Reduce cost of goods (COGs).

License the platform  →
– Path B

Strategic partnerships.

Asset co-development – your pipeline or ours – for risk-sharing and validation.

Co-develop with us  →
— Latest news / resources

Latest news /
resources.

Science 2026 · 05 · 28

New TFG-001 preclinical data at the 7th World Parkinson Congress.

Resources 2026 · 05 · 22

In the Stem Cell Jungle #3

Resources 2026 · 05 · 05

In the Stem Cell Jungle #2

All news  →